AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10799368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 20:30 g
Number of subjects: 81
Study 10799368 — intervention group
Group type: COMPARATOR
Intervention: Control group (casein 0:50 g)
Number of subjects: 81
Study 10799368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 30 g
Number of subjects: 81
Study 10799368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 40 g
Number of subjects: 81
Study 8970834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioartificial liver (BAL) treatment for FHF patients
Number of subjects: 20
Study 8970834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioartificial liver (BAL) treatment for chronic liver failure patients
Number of subjects: 20
Study 1568544 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent citrate-cimetidine combination (200 mg cimetidine/tablet)
Number of subjects: 12
Study 1568544 — intervention group
Group type: COMPARATOR
Intervention: Liquid aluminium-magnesium hydroxide antacid
Number of subjects: 12
Study 1568544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2860133 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 45
Study 2860133 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 45
Study 2860133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 45
Study 2860133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29931231 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (300 g daily containing 108 colony-forming units Bifidobacterium animalis/mL and 1.5 g inulin)
Number of subjects: 102
Study 29931231 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional yogurt (daily)
Number of subjects: 102
Study 29931231 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle advice (control group)
Number of subjects: 102
Study 27803925 — intervention group
Group type: EXPERIMENTAL
Intervention: VAWI treatment (group B)
Number of subjects: 40
Study 27803925 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (group A)
Number of subjects: 40
Study 24815948 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive valence words
Number of subjects: 0
Study 24815948 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal words
Number of subjects: 0
Study 24815948 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium and low arousal words
Number of subjects: 0
Study 24815948 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral and negative words
Number of subjects: 0
Study 24815948 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive words
Number of subjects: 0
Study 24815948 — intervention group
Group type: EXPERIMENTAL
Intervention: Early posterior negativity (EPN) in ERPs
Number of subjects: 0
Study 24815948 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal
Number of subjects: 0
Study 22112212 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary native language discharge summary
Number of subjects: 130
Study 22112212 — intervention group
Group type: COMPARATOR
Intervention: Control group (English discharge summary)
Number of subjects: 130
Study 20537164 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg flat dose, subcutaneously)
Number of subjects: 44
Study 20537164 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 44
Study 20537164 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 44
Study 18930575 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser fluorescence device (DIAGNOdent pen, KaVo)
Number of subjects: 120
Study 16195054 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference-based approach (IBA)
Number of subjects: 54
Study 16195054 — intervention group
Group type: COMPARATOR
Intervention: Cognitive appraisal model (CAM)
Number of subjects: 54
Study 16195054 — intervention group
Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 54
Study 11830196 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors (hirudin, bivalirudin, argatroban, efegatran, or inogatran)
Number of subjects: 35970
Study 11830196 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 35970
Study 10622066 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori test-and-treat strategy
Number of subjects: 232
Study 10622066 — intervention group
Group type: COMPARATOR
Intervention: Referral to direct access endoscopy (control)
Number of subjects: 232
Study 7781397 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation
Number of subjects: 0
Study 7781397 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 7781397 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy, magnetic resonance imaging, endoesophageal ultrasound, and/or surgical staging
Number of subjects: 0
Study 7781397 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 trials of chemoradiation
Number of subjects: 0
Study 7781397 — intervention group
Group type: COMPARATOR
Intervention: Randomized multi‐institutional trials
Number of subjects: 0
Study 2160665 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine ACTH 1-39 (1.5 U)
Number of subjects: 0
Study 2160665 — intervention group
Group type: EXPERIMENTAL
Intervention: h-CRH (25 micrograms)
Number of subjects: 0
Study 2160665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7006236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine treatment
Number of subjects: 84
Study 7006236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 31736439 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 38
Study 31196501 — intervention group
Group type: EXPERIMENTAL
Intervention: Elental® (treatment group)
Number of subjects: 22
Study 31196501 — intervention group
Group type: COMPARATOR
Intervention: Control diet (control group)
Number of subjects: 22
Study 27695989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level exercise echocardiography (measured E/e' at rest and during low-level exercise)
Number of subjects: 60
Study 27695989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level exercise echocardiography
Number of subjects: 60
Study 26306902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (arm B)
Number of subjects: 46
Study 26306902 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (arm A)
Number of subjects: 46
Study 23508747 — intervention group
Group type: EXPERIMENTAL
Intervention: IMC-facilitated approach (Group B)
Number of subjects: 42
Study 23508747 — intervention group
Group type: COMPARATOR
Intervention: Conventional single transseptal big CB approach (Group A)
Number of subjects: 42
Study 23508747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 21985880 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrushes under supervised conditions
Number of subjects: 200
Study 21985880 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrushes under unsupervised conditions
Number of subjects: 200
Study 21985880 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrushes under supervised conditions
Number of subjects: 200
Study 21985880 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrushes under unsupervised conditions
Number of subjects: 200
Study 21985880 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised brushing (both brushes)
Number of subjects: 200
Study 21985880 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised brushing (both brushes)
Number of subjects: 200
Study 19197740 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive tutorial
Number of subjects: 0
Study 19197740 — intervention group
Group type: COMPARATOR
Intervention: Passive tutorial
Number of subjects: 0
Study 19197740 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for tutorial type
Number of subjects: 0
Study 17463072 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFN beta-1a) therapy
Number of subjects: 54
Study 17463072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study 15927922 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg daily for 3 months)
Number of subjects: 12
Study 15927922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15927922 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (150 microg/ml incubation)
Number of subjects: 12
Study 15927922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (incubation)
Number of subjects: 12
Study 11487602 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise (after 10 weeks of supervised weight-lifting)
Number of subjects: 32
Study 11487602 — intervention group
Group type: COMPARATOR
Intervention: Control group (lectures for 10 weeks)
Number of subjects: 32
Study 10960463 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Intron 0.35, 0.7, or 1.4 microg/kg subcutaneously weekly for 24 weeks plus ribavirin 600, 800, or 1,000 to 1,200 mg orally daily.
Number of subjects: 72
Study 10960463 — intervention group
Group type: COMPARATOR
Intervention: PEG‐Intron alone (0.35, 0.7, or 1.4 microg/kg subcutaneously weekly for 24 weeks).
Number of subjects: 72
Study 8704698 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant
Number of subjects: 42
Study 8704698 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant (4 months later)
Number of subjects: 42
Study 8704698 — intervention group
Group type: COMPARATOR
Intervention: Pre-transplant
Number of subjects: 42
Study 1899892 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of the central nervous system (CNS) in schistosomiasis mansoni
Number of subjects: 0
Study 1899892 — intervention group
Group type: COMPARATOR
Intervention: CNS involvement associated with hepatosplenic and cardiopulmonary forms
Number of subjects: 0
Study 6661380 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam (0.25 mg)
Number of subjects: 0
Study 6661380 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0
Study 6661380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31590438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplementation (twice-a-day for 2 years)
Number of subjects: 180
Study 31590438 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 180
Study 29122463 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of TDV 3 months apart (group 1)
Number of subjects: 1800
Study 29122463 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of TDV (group 2)
Number of subjects: 1800
Study 29122463 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of TDV and a booster dose 1 year later (group 3)
Number of subjects: 1800
Study 29122463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 1800
Study 29122463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-related unsolicited adverse events
Number of subjects: 1800
Study 29122463 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic, virologically confirmed dengue
Number of subjects: 1800
Study 27575577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at GV 26, Ex‐HN 3, bilateral LI 4, and ST 36 for 10 minutes
Number of subjects: 11
Study 27575577 — intervention group
Group type: COMPARATOR
Intervention: Control session without acupuncture
Number of subjects: 11
Study 27575577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 11
Study 24594833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve M-16V (3×10^9 cfu/day)
Number of subjects: 159
Study 24594833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 159
Study 24594833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 159
Study 22492766 — intervention group
Group type: EXPERIMENTAL
Intervention: Written gestational age‐specific information 1 hour before verbal counseling
Number of subjects: 60
Study 22492766 — intervention group
Group type: COMPARATOR
Intervention: Gestational age‐specific verbal information
Number of subjects: 60
Study 20156983 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (0.25 ms, 100 Hz, 15 mA)
Number of subjects: 18
Study 20156983 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 18
Study 18612053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group patients included their chosen support person in the education session and the support persons received newsletters.
Number of subjects: 199
Study 18612053 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned but implied as those who did not include a support person in the education session).
Number of subjects: 199
Study 16098418 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 1205
Study 16098418 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1205
Study 16098418 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1205
Study 11918762 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 27
Study 11918762 — intervention group
Group type: COMPARATOR
Intervention: nandrolone decanoate (ND; 200 mg/week IM)
Number of subjects: 27
Study 10633516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroshield (F releasing filled fissure sealant)
Number of subjects: 112
Study 10633516 — intervention group
Group type: COMPARATOR
Intervention: Delton (non-F nonfilled fissure sealant)
Number of subjects: 112
Study 7495346 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute rheumatic fever and chronic rheumatic heart disease
Number of subjects: 60
Study 7495346 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with rheumatic fever
Number of subjects: 60
Study 7495346 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 60
Study 1851824 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0‐g sodium alginate supplement (algae‐isolate, 75% soluble fiber)
Number of subjects: 7
Study 30239620 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEPmate (text-messaging intervention)
Number of subjects: 121
Study 30239620 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 121
Study 29908053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality physical activity features in Madison County parks (mean, 13)
Number of subjects: 19
Study 29908053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality physical activity amenities in Madison County parks (mean, 25.8)
Number of subjects: 19
Study 29908053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality incivilities in Madison County parks (mean, 1.6)
Number of subjects: 19
Study 29908053 — intervention group
Group type: EXPERIMENTAL
Intervention: Total neighborhood parks quality physical activity resources (QPAR) index (mean, 28.7)
Number of subjects: 19
Study 26942320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist ropinirole 0.5 mg
Number of subjects: 0
Study 26942320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist ropinirole 1.0 mg
Number of subjects: 0
Study 26942320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24781725 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (12.5 mg, 0.1 µg kg(‐1) per min; n = 17)
Number of subjects: 33
Study 24781725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study 21975558 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate 2 mg bimonthly
Number of subjects: 756
Study 21975558 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate 3 mg quarterly
Number of subjects: 756
Study 21975558 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate (previously treated with daily oral ibandronate or placebo IV)
Number of subjects: 756
Study 21975558 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate (both regimens)
Number of subjects: 756
Study 20499255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg nafamostat mesilate diluted in a 5% glucose solution
Number of subjects: 90
Study 20499255 — intervention group
Group type: COMPARATOR
Intervention: 1.5 ml 5% glucose solution (Control)
Number of subjects: 90
Study 18065333 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg/day
Number of subjects: 54
Study 18065333 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100 mg/day
Number of subjects: 54
Study 16118802 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent cancer diagnosis (R group)
Number of subjects: 227
Study 16118802 — intervention group
Group type: COMPARATOR
Intervention: Disease-free status (DF group)
Number of subjects: 227
Study 12358871 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention with feedback reports and support from a facilitator
Number of subjects: 185
Study 12358871 — intervention group
Group type: COMPARATOR
Intervention: Control group with no special attention
Number of subjects: 185
Study 12358871 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 185
Study 10662480 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP/MTZ i.v./PO (ciprofloxacin plus metronidazole, intravenous to oral)
Number of subjects: 446
Study 10662480 — intervention group
Group type: COMPARATOR
Intervention: CIP/MTZ i.v. or IMI i.v. (ciprofloxacin plus metronidazole intravenous or imipenem-cilastatin intravenous)
Number of subjects: 446
Study 10662480 — intervention group
Group type: COMPARATOR
Intervention: IMI i.v. (imipenem-cilastatin intravenous)
Number of subjects: 446
Study 10662480 — intervention group
Group type: COMPARATOR
Intervention: CIP/MTZ i.v. (ciprofloxacin plus metronidazole intravenous)
Number of subjects: 446
Study 7779645 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (500 mg pessary and 1% cream)
Number of subjects: 229
Study 7779645 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg bd oral dose for 1 day)
Number of subjects: 229
Study 7779645 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (150 mg single oral dose)
Number of subjects: 229
Study 2178597 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (various doses)
Number of subjects: 124
Study 2178597 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone sodium phosphate
Number of subjects: 124
Study 6932834 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 9
Study 6932834 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 9
Study 31404106 — intervention group
Group type: EXPERIMENTAL
Intervention: MNS autoantibody assay (combination of four autoantibodies and free/total PSA ratio)
Number of subjects: 99
Study 31404106 — intervention group
Group type: EXPERIMENTAL
Intervention: MNS autoantibody assays for four autoantibodies (PARK7, TARDBP, TLN1, CALD1)
Number of subjects: 99
Study 31404106 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA and free PSA
Number of subjects: 99
Study 27933431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 16
Study 27933431 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 16
Study 25308244 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous e-learning (SeL)
Number of subjects: 0
Study 25308244 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face (FtF) teaching
Number of subjects: 0
Study 25308244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 24965659 — intervention group
Group type: EXPERIMENTAL
Intervention: Head CT Choice decision aid
Number of subjects: 0
Study 24965659 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22782331 — intervention group
Group type: EXPERIMENTAL
Intervention: IP (irinotecan/cisplatin)
Number of subjects: 146
Study 22782331 — intervention group
Group type: EXPERIMENTAL
Intervention: IP + ISMN (irinotecan/cisplatin with isosorbide-5-mononitrate)
Number of subjects: 146
Study 22782331 — intervention group
Group type: EXPERIMENTAL
Intervention: IX (irinotecan/capecitabine)
Number of subjects: 146
Study 22782331 — intervention group
Group type: EXPERIMENTAL
Intervention: IX + ISMN (irinotecan/capecitabine with isosorbide-5-mononitrate)
Number of subjects: 146
Study 19008238 — intervention group
Group type: EXPERIMENTAL
Intervention: PMOP(enhanced)
Number of subjects: 41
Study 19008238 — intervention group
Group type: COMPARATOR
Intervention: Control (standard pacing)
Number of subjects: 41
Study 16153327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-fortified maize meal (with vitamin A, thiamine, riboflavin, and pyridoxine) for 12 months
Number of subjects: 60
Study 16153327 — intervention group
Group type: COMPARATOR
Intervention: Unfortified maize meal for 12 months
Number of subjects: 60
Study 16153327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-fortified maize meal
Number of subjects: 60
Study 16153327 — intervention group
Group type: COMPARATOR
Intervention: Unfortified maize meal
Number of subjects: 60
Study 12854478 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of fentanyl (1 microgram.kg‐1 before operation and 0.02 microgram.kg‐1.min‐1 during operation) and propofol (4‐10 mg.kg‐1.min‐1)
Number of subjects: 0
Study 10372614 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal feeds (D)
Number of subjects: 80
Study 10372614 — intervention group
Group type: COMPARATOR
Intervention: Gastric feeds (G)
Number of subjects: 80
Study 8911982 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (bicycle ergometer for 1 hour at pulse rate 120 bpm)
Number of subjects: 167
Study 8911982 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride with exercise
Number of subjects: 167
Study 8911982 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide with exercise
Number of subjects: 167
Study 8911982 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 167